

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) January 26, 2005  
-----

BECTON, DICKINSON AND COMPANY

-----  
(Exact Name of Registrant as Specified in Its Charter)

New Jersey

-----  
(State or Other Jurisdiction of Incorporation)

001-4802

22-0760120

-----  
(Commission File Number)

(IRS Employer Identification No.)

1 Becton Drive, Franklin Lakes, New Jersey

07417-1880

-----  
(Address of Principal Executive Offices)

(Zip Code)

(201) 847-6800

-----  
(Registrant's Telephone Number, Including Area Code)

N/A

-----  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On January 26, 2005, Becton, Dickinson and Company ("BD") issued a press release announcing its financial results for the first fiscal quarter of fiscal year 2005. A copy of the press release is furnished as Exhibit 99.1 to this report.

The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those under U.S. generally accepted accounting principals (GAAP), as follows:

- o We present revenue growth rates at constant foreign exchange rates. We believe that presenting growth rates at constant foreign exchange rates allows investors to view the underlying operating results of BD and of its segments without the impact of fluctuations in foreign currency exchange rates, thereby facilitating comparisons to prior periods.
- o We present earnings per share and other financial measures after excluding the impact of significant charges, and the impact of unusual or non-recurring items. We believe that excluding such impact from these financial measures allows investors to more easily compare BD's

financial performance with prior period performance and to understand the operating results of BD without the effects of these significant charges and unusual or non-recurring items.

- o We present earnings per share and other financial measures after excluding the impact of share-based compensation expense for the period, to the extent such period is being compared to a prior period where such expense was either not recognized or was immaterial. We believe that excluding these expenses, which are non-cash items, allows investors to more easily compare BD's financial performance with prior period performance.
- o We present earnings per share and other financial measures after excluding the effects of changes in tax laws and regulations (including without limitation, rate changes) and other events that cause the tax rate for the period being presented to vary from the Company's expected effective tax rate for the full fiscal year. We believe that excluding such effects facilitates comparisons of BD's financial performance with prior period performance.

BD's management considers these non-GAAP financial measures internally in evaluating BD's performance. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

Item 9.01 Financial Statements and Exhibits

(c) Exhibits.

Exhibit 99.1 Press release dated January 26, 2005, which is furnished pursuant to Item 2.02.

<Page>

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY  
(Registrant)

By: /s/ Dean J. Paranicas  
-----  
Dean J. Paranicas  
Vice President, Corporate  
Secretary and Public Policy

Date: January 26, 2005

<Page>

#### INDEX TO EXHIBITS

Exhibit Number	Description of Exhibits
99.1	Press release dated January 26, 2005, which is furnished pursuant to Item 2.02.

STATEMENT OF DIFFERENCES

The trademark symbol shall be expressed as.....'TM'

## Contact:

Patricia A. Spinella, Investor Relations - 201-847-5453  
Colleen T. White, Corporate Communications - 201-847-5369

## BD ANNOUNCES RESULTS FOR FISCAL FIRST QUARTER

Franklin Lakes, NJ (January 26, 2005) - BD (Becton, Dickinson and Company) (NYSE: BDX) today reported record quarterly revenues of \$1.288 billion for the fiscal first quarter ended December 31, 2004, representing an increase of 9 percent from the same period a year ago. At constant foreign exchange rates, revenues increased 6 percent for the quarter. Revenue growth in all segments benefited from favorable foreign currency translation, particularly with respect to the Euro.

"We're off to a strong start for fiscal 2005 with all business segments contributing solid results. Our global revenue growth, disciplined cost control and supply chain productivity continue to deliver earnings increases," said Edward J. Ludwig, Chairman, President and Chief Executive Officer. "This strong performance is enabling us to increase our investments in innovation and growth for the future."

Reported diluted earnings per share for the first quarter were 75 cents. On October 4, 2004, BD announced that a plan had been initiated to offer Clontech, a unit of the BD Biosciences segment, for sale; therefore, the results of operations from Clontech have been classified as "discontinued operations." Income from discontinued operations for the first quarter of \$1.0 million is less than 1 cent per diluted share; however, due to rounding, diluted earnings per share from continuing operations were 74 cents.

## Analyses of First Quarter Fiscal Year 2005 and 2004 Earnings

The following analyses of diluted earnings per share from continuing operations have been provided to reconcile to pro forma diluted earnings per share from continuing operations for the first quarters of fiscal 2005 and 2004.

<Table>  
<Caption>

Three Months Ended December 31, -----	(Q1 FY2005) 2004 -----	(Q1 FY2004) 2003 -----	% Increase -----
<S>	<C>	<C>	<C>
Diluted EPS from Continuing Operations:	\$0.74	\$ 0.48	54%
	-----	-----	
Pro Forma Adjustments:			
Tax Examinations(1)	(0.04)	--	
Tax Rate Impact(2)	(0.02)	--	
Share-Based Compensation Expense(3)	0.03	--	
BGM Charge(4)	--	0.11	
	-----	-----	
Rounding	(0.03)	0.11	
	-----	-----	
Pro Forma Diluted EPS from Continuing Operations:	\$0.71	\$ 0.58	22%
	=====	=====	

</Table>

(1) Included in diluted earnings per share from continuing operations for the first quarter of fiscal 2005 is approximately 4 cents per diluted share due to the reversal of tax reserves in connection with the conclusion of tax examinations in four non-U.S. jurisdictions.

(2) Represents the effect on diluted earnings per share from continuing operations of tax-related events that caused the quarter's tax rate to vary from the expected effective tax rate for the year. The expected effective tax rate for the year, without taking into account the tax

impact of the items described in notes (1) and (3) herein, is 25.5%.

(3) Included in diluted earnings per share from continuing operations is approximately 3 cents per diluted share related to share-based compensation expense recorded in connection with the early adoption of FASB Statement No. 123 (revised), and the restricted stock awards granted under the new long-term incentive program, both of which occurred this quarter and are described below.

(4) Included in the first quarter of fiscal 2004 diluted earnings per share from continuing operations is a charge of 11 cents per diluted share related to the voluntary recall and write-off of certain blood glucose strip inventory and other actions taken with respect to our blood glucose monitoring products.

Based on the foregoing analyses, pro forma diluted earnings per share from continuing operations of 71 cents for the fiscal first quarter of 2005 increased by 22 percent over pro forma diluted earnings per share from continuing operations of 58 cents for the fiscal first quarter of 2004.

#### Share-Based Compensation

As planned, effective October 1, 2004, the Company adopted FASB Statement No.123 (revised) relating to the expensing of share-based incentive awards. Diluted earnings per share from continuing operations for the first quarter included 3 cents of share-based compensation expense associated with the adoption and the restricted stock awards granted under the new long-term incentive program, which consisted of a mix of performance-based restricted stock awards, time-vested restricted stock awards and stock options or stock appreciation rights. We estimate that total share-based compensation expense for the fiscal year 2005 will be about 17 cents per diluted share.

#### Segment Results

In the BD Medical segment, worldwide revenues for the quarter were \$694 million, representing an increase of 11 percent over the prior year period. BD Medical revenues reflect the continued conversion in the U.S. to safety-engineered products, accounting for sales of \$126 million compared with \$114 million in the prior year's quarter. Included in BD Medical revenues were international sales of safety-engineered products of \$18 million, compared with \$14 million in the prior year's quarter. Also contributing to the growth of the segment were strong sales in the Diabetes Care unit.

In the BD Diagnostics segment, worldwide revenues for the quarter were \$414 million, representing an increase of 3 percent over the prior year period. Revenue growth of 13 percent in the Preanalytical Systems unit of the segment reflects the continued conversion in the U.S. to safety-engineered products, accounting for sales of \$86 million, compared with \$76 million in the prior year's quarter. Included in Preanalytical Systems revenues were international sales of safety-engineered products of \$42 million, compared with \$29 million in the prior year's quarter. As anticipated, and despite strong sales from the BD ProbeTec™ ET and BD Phoenix™ instruments, revenues in the Diagnostic Systems unit of the segment declined 5 percent from the prior year's quarter. The first quarter of fiscal 2004 benefited from exceptionally strong sales of flu tests in Japan and the U.S., which did not recur in this year's fiscal first quarter.

In the BD Biosciences segment, worldwide revenues from continuing operations for the quarter were \$181 million, representing an increase of 15 percent over the prior year period. Instrument revenue growth was primarily driven by sales of the recently launched BD FACSCanto™ analyzer. Continued strong market acceptance of the BD FACSAria™ cell sorter also contributed to sales. First quarter sales of flow cytometry reagents were also strong in both the clinical and research markets.

#### Geographic Results

First quarter revenues in the U.S. of \$624 million represented an increase of 7 percent over the prior year period. Revenues outside the U.S. of \$664 million represented an increase of 11 percent over the prior year period, or 5 percent at constant foreign exchange rates.

Fiscal 2005 Outlook for Second Quarter and Full Year

The following analyses of estimated diluted earnings per share from continuing operations have been provided to reconcile to estimated pro forma diluted earnings per share from continuing operations for the fiscal 2005 second quarter and full year.

<TABLE>  
<CAPTION>

----- Estimated Increase -----	Quarter 2			Full Year		
	FY2005	FY2004	% Increase	FY2005	FY2004	%
<S>	<C>	<C>	<C>	<C>	<C>	<C>
Diluted EPS from Continuing Operations: 25%-27%	\$0.64-\$0.65 (1)	\$ 0.62	3%-5%	\$2.76-\$2.81 (1)	\$ 2.21	-
-----	-----	-----	-----	-----	-----	-----
Pro Forma Adjustments:						
Tax Examinations(2)	-	-		(0.04)	-	
Tax Rate Impact(3)	0.020	-		-	-	
Share-Based Compensation Expense(4)	0.045	-		0.17	-	
BGM Charges (5)	-	-		-	0.11	
Litigation Settlement(5)	-	-		-	0.24	
	-----	-----		-----	-----	
	0.065	-		0.13	0.35	
	-----	-----		-----	-----	
Pro Forma Diluted EPS from Continuing Operations: 13%-15%	\$0.70-\$0.72	\$ 0.62	13%-16%	\$2.89-\$2.94	\$ 2.56	
=====	=====	=====	=====	=====	=====	

</TABLE>

(1) Fiscal 2005 second quarter and full year estimated diluted earnings per share from continuing operations do not include the impact on taxes that would result if the Company were to repatriate certain undistributed earnings of foreign subsidiaries under the American Jobs Creation Act of 2004.

(2) Represents diluted earnings per share from continuing operations due to the reversal of tax reserves in the first quarter in connection with the conclusion of tax examinations in four non-U.S. jurisdictions.

(3) Represents the effect on diluted earnings per share from continuing operations of tax-related events that causes the quarter's tax rate to vary from the expected effective tax rate for the year. The expected effective tax rate for the year, without taking into account the tax impact of the items described in notes (1), (2) and (4) herein, is 25.5%.

(4) Represents the effect on diluted earnings per share from continuing operations relating to share-based compensation expense associated with the early adoption of FASB Statement No. 123 (revised), and the restricted stock awards granted under the new long-term incentive program.

(5) Included in full year fiscal 2004 diluted earnings per share from continuing operations was a third quarter charge of 24 cents per diluted share related to the settlement of the Retractable Technologies, Inc. litigation, in addition to the previously noted first quarter BGM charge of 11 cents per diluted share.

The Company estimates that second quarter 2005 pro forma diluted earnings per share from continuing operations will increase in the range of 13 to 16 percent as compared with fiscal second quarter 2004 diluted earnings per share from continuing operations of 62 cents.

The Company also estimates pro forma diluted earnings per share from continuing operations for fiscal 2005 will increase in the range of 13 to 15 percent compared with fiscal 2004 pro forma diluted earnings per share from continuing operations of \$2.56.

A conference call regarding BD's first quarter results and its expectations for the second quarter and full fiscal year will be broadcast live on BD's website, [www.bd.com/investors](http://www.bd.com/investors), at 10:00 a.m. (ET) Wednesday, January 26, 2005. The conference call will be available for replay on BD's website, [www.bd.com/investors](http://www.bd.com/investors), or at 1-800-475-6701 (domestic) and 1-320-365-3844 (international) through the close of business on February 2, 2005.

This news release contains certain non-GAAP financial measures. A reconciliation of these and other measures to the comparable GAAP measures is included in this release and in the attached financial tables.

BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. For the fiscal year ended September 30, 2004, BD reported total revenues of \$4.935 billion.

\*\*\*

This press release, including the section entitled "Fiscal 2005 Outlook for Second Quarter and Full Year," contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs and their effect on, among other things, the cost of producing the Company's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission) and changes in healthcare or other governmental regulation; issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY  
CONSOLIDATED INCOME STATEMENTS  
(Unaudited; Amounts in thousands, except per-share data)

<TABLE>  
<CAPTION>

	Three Months Ended December 31,		
	2004	2003	% Change
<S>	<C>	<C>	<C>
REVENUES	\$ 1,288,369	\$ 1,185,120	8.7
Cost of products sold	634,501 (1)	634,255 (2)	0.0
Selling and administrative	341,088 (1)	324,097	5.2
Research and development	62,083 (1)	58,288	6.5
TOTAL OPERATING COSTS AND EXPENSES	1,037,672	1,016,640	2.1
OPERATING INCOME	250,697	168,480	48.8
Interest expense, net	(9,122)	(8,928)	2.2
Other expense, net	(2,861)	(911)	NM

INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	238,714	158,641	50.5
Income tax provision	44,316	33,716	31.4
-----			
INCOME FROM CONTINUING OPERATIONS	194,398	124,925	55.6
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAXES OF \$623 IN 2005 AND \$281 IN 2004, RESPECTIVELY	953	477	NM
-----			
NET INCOME	\$ 195,351	\$ 125,402	55.8
-----			
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 0.77	\$ 0.49	57.1
Income from discontinued operations	\$ - (3)	\$ -	-
Net income	\$ 0.78	\$ 0.50	56.0
Diluted:			
Income from continuing operations	\$ 0.74	\$ 0.48	54.2
Income from discontinued operations	\$ - (3)	\$ -	-
Net income	\$ 0.75	\$ 0.48	56.3
-----			
AVERAGE SHARES OUTSTANDING			
Basic	251,232	252,132	
Diluted	261,970	261,872	
-----			

</TABLE>

NM - Not Meaningful

- (1) Includes share-based compensation expense relating to the adoption of SFAS No. 123 (revised).
- (2) Includes a \$45,024 charge associated with blood glucose monitoring (BGM) products.
- (3) Includes income of less than \$0.01 of diluted earnings per share, however due to rounding, basic and diluted EPS is \$0.01 higher than basic and diluted earnings per share from continuing operations.

Page 1

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
Three Months Ended December 31,  
(Unaudited; Amounts in thousands, except per-share data)

<TABLE>  
<CAPTION>

	2004 (Q1 FY2005)			
	As	Share-Based	Tax	Tax Rate
Excluding	Reported	Compensation (1)	Examinations (2)	Impact (3)
Items	-----			
<S>	<C>	<C>	<C>	<C>
<C>				
Cost of products sold	\$ 634,501	\$ (1,548)	\$ -	\$ -
\$ 632,953				
as a % of revenues	49.2%			
49.1%				



Gross profit	653,868	1,548	-	-
655,416				
as a % of revenues	50.8%			
0.9%				
Selling and administrative	341,088	(9,108)	-	-
331,980				
as a % of revenues	26.5%			
25.8%				
Research and development	62,083	(934)	-	-
61,149				
as a % of revenues	4.8%			
4.7%				
Operating Income	250,697	11,590	-	-
262,287				
as a % of revenues	19.5%			
20.4%				
Income taxes	44,316	3,096	11,265	5,150
63,827				
effective tax rate	18.6%			
25.5%				
Income from continuing operations	194,398	8,494	(11,265)	(5,150)
186,477				
as a % of revenues	15.1%			
14.5%				
Diluted earnings per share				
Income from continuing operations	0.74	0.03	(0.04)	(0.02)
0.71				
Income from discontinued operations (4)	-	-	-	-
-				
Diluted earnings per share	0.75	0.03	(0.04)	(0.02)
0.72				

</TABLE>

- (1) Relates to the adoption of SFAS No. 123 (revised), "Share-Based Payment". Fiscal 2004 amounts have not been restated.
- (2) Relates to the reversal of tax reserves in connection with the conclusion of tax examinations in four non-U.S. jurisdictions.
- (3) Represents the effect on diluted earnings per share from continuing operations of tax-related events that caused the quarter's tax rate to vary from the expected effective tax rate for the year. The expected effective tax rate for the year, without taking into account the tax impact of items described in notes (1) and (2) herein, is 25.5%.
- (4) Includes income of less than \$0.01 of diluted earnings per share, however due to rounding, basic and diluted EPS is \$0.01 higher than basic and diluted earnings per share from continuing operations.

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
Three Months Ended December 31,  
(Unaudited; Amounts in thousands, except per-share data)

<TABLE>  
<CAPTION>

	2003 (Q1 FY2004)		
	As Reported	BGM Charges (5)	Excluding Charges
<S>	<C>	<C>	<C>
Gross Profit	\$ 550,865	\$ 45,024	\$ 595,889
as a % of revenues	46.5%		50.3%
Operating Income	168,480	45,024	213,504
as a % of revenues	14.2%		18.0%
Income from continuing operations	124,925	27,915	152,840
as a % of revenues	10.5%		12.9%
Diluted earnings per share			
Income from continuing operations	0.48	0.11	0.58
Income from discontinued operations (4)	-	-	-

Diluted earnings per share 0.48 0.11 0.59  
 </TABLE>

(4) Includes income of less than \$0.01 of diluted earnings per share, however due to rounding, basic and diluted EPS is \$0.01 higher than basic and diluted earnings per share from continuing operations.

(5) Relates to the fiscal 2004 charge associated with blood glucose monitoring (BGM) products.

Page 2

BECTON DICKINSON AND COMPANY  
 SUPPLEMENTAL REVENUE INFORMATION  
 REVENUES BY SEGMENT AND GEOGRAPHIC AREA  
 (Unaudited; Amounts in thousands)

<TABLE>  
 <CAPTION>

	Three Months Ended December 31,		
	2004	2003	% Change
<S>	<C>	<C>	<C>
BD MEDICAL			
United States	\$ 329,654	\$ 303,748	8.5
International	364,168	323,120	12.7
TOTAL	\$ 693,822	\$ 626,868	10.7
BD DIAGNOSTICS			
United States	\$ 218,708	\$ 212,917	2.7
International	195,075	188,028	3.7
TOTAL	\$ 413,783	\$ 400,945	3.2
BD BIOSCIENCES			
United States	\$ 75,697	\$ 68,176	11.0
International	105,067	89,131	17.9
TOTAL	\$ 180,764	\$ 157,307	14.9
TOTAL REVENUES			
United States	\$ 624,059	\$ 584,841	6.7
International	664,310	600,279	10.7
TOTAL	\$ 1,288,369	\$ 1,185,120	8.7

</TABLE>

Page 3

BECTON DICKINSON AND COMPANY  
 SUPPLEMENTAL REVENUE INFORMATION  
 REVENUES BY BUSINESS SEGMENTS AND UNITS  
 Three Months Ended December 31,  
 (Unaudited; Amounts in thousands)

<TABLE>  
 <CAPTION>

United States		
2004	2003	% Change

<S>	<C>	<C>	<C>
BD MEDICAL			
Medical Surgical Systems	\$ 215,506	\$ 198,519	8.6
Diabetes Care	88,461	74,849	18.2
Pharmaceutical Systems	20,049	24,355	(17.7)
Ophthalmic Systems	5,638	6,025	(6.4)
TOTAL	\$ 329,654	\$ 303,748	8.5
BD DIAGNOSTICS			
Preanalytical Systems	\$ 114,763	\$ 106,627	7.6
Diagnostic Systems	103,945	106,290	(2.2)
TOTAL	\$ 218,708	\$ 212,917	2.7
BD BIOSCIENCES			
Discovery Labware	\$ 24,094	\$ 23,415	2.9
Immunocytometry Systems	34,694	28,768	20.6
Pharmingen	16,909	15,993	5.7
TOTAL	\$ 75,697	\$ 68,176	11.0
TOTAL UNITED STATES	\$ 624,059	\$ 584,841	6.7

</TABLE>

Page 4

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended December 31, (continued)  
(Unaudited; Amounts in thousands)

<TABLE>  
<CAPTION>

<S>	International				
	2004	2003	% Change		
			Reported	FX Neutral	FX Impact
<C>	<C>	<C>	<C>	<C>	
BD MEDICAL					
Medical Surgical Systems	\$ 194,058	\$ 176,324	10.1	4.6	5.5
Diabetes Care	70,217	58,177	20.7	14.1	6.6
Pharmaceutical Systems	90,636	80,844	12.1	4.9	7.2
Ophthalmic Systems	9,257	7,775	19.1	11.5	7.6
TOTAL	\$ 364,168	\$ 323,120	12.7	6.6	6.1
BD DIAGNOSTICS					
Preanalytical Systems	\$ 93,758	\$ 78,353	19.7	13.1	6.6
Diagnostic Systems	101,317	109,675	(7.6)	(12.4)	4.8
TOTAL	\$ 195,075	\$ 188,028	3.7	(1.8)	5.5
BD BIOSCIENCES					
Discovery Labware	\$ 22,869	\$ 21,468	6.5	0.7	5.8
Immunocytometry Systems	65,406	53,318	22.7	15.9	6.8
Pharmingen	16,792	14,345	17.1	11.1	6.0
TOTAL	\$ 105,067	\$ 89,131	17.9	11.5	6.4
TOTAL INTERNATIONAL	\$ 664,310	\$ 600,279	10.7	4.7	6.0

</TABLE>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended December 31, (continued)  
(Unaudited; Amounts in thousands)

<TABLE>  
<CAPTION>

	Total				
	2004	2003	% Change		
			Reported	FX Neutral	FX Impact
<S>	<C>	<C>	<C>	<C>	<C>
BD MEDICAL					
Medical Surgical Systems	\$ 409,564	\$ 374,843	9.3	6.7	2.6
Diabetes Care	158,678	133,026	19.3	16.4	2.9
Pharmaceutical Systems	110,685	105,199	5.2	(0.4)	5.6
Ophthalmic Systems	14,895	13,800	7.9	3.7	4.2
TOTAL	\$ 693,822	\$ 626,868	10.7	7.5	3.2
BD DIAGNOSTICS					
Preanalytical Systems	\$ 208,521	\$ 184,980	12.7	9.9	2.8
Diagnostic Systems	205,262	215,965	(5.0)	(7.4)	2.4
TOTAL	\$ 413,783	\$ 400,945	3.2	0.6	2.6
BD BIOSCIENCES					
Discovery Labware	\$ 46,963	\$ 44,883	4.6	1.8	2.8
Immunocytometry Systems	100,100	82,086	21.9	17.6	4.3
Pharmingen	33,701	30,338	11.1	8.3	2.8
TOTAL	\$ 180,764	\$ 157,307	14.9	11.3	3.6
TOTAL REVENUES	\$ 1,288,369	\$ 1,185,120	8.7	5.7	3.0

</TABLE>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
Three Months Ended,  
(Unaudited; Amounts in thousands)

2004 International Safety Revenues

<TABLE>  
<CAPTION>

Segment	International Safety Revenues			
	December 31, 2003	March 31, 2004	June 30, 2004	September 30, 2004
Total				
<S>	<C>	<C>	<C>	<C>
Medical	\$ 14,484	\$ 16,794	\$ 15,952	\$ 16,040
\$ 63,270				

Diagnostics 140,044	29,431	34,388	36,925	39,300
-----	-----	-----	-----	-----
Total \$ 203,314	\$ 43,915	\$ 51,182	\$ 52,877	\$ 55,340
=====	=====	=====	=====	=====

2004 U.S. Safety Revenues (revised) (\*)

<TABLE>  
<CAPTION>

	U.S. Safety Revenues (revised)			
	December 31, 2003	March 31, 2004	June 30, 2004	September 30, 2004
-----	-----	-----	-----	-----
Segment Total				
-----	-----	-----	-----	-----
<S> <C>	<C>	<C>	<C>	<C>
Medical \$ 458,951	\$ 114,360	\$ 109,901	\$ 113,179	\$ 121,511
Diagnostics 316,514	75,626	75,354	80,157	85,377
-----	-----	-----	-----	-----
Total \$ 775,465	\$ 189,986	\$ 185,255	\$ 193,336	\$ 206,888
=====	=====	=====	=====	=====

<TABLE>  
<CAPTION>

	U.S. Safety Revenues (previously reported)			
	December 31, 2003	March 31, 2004	June 30, 2004	September 30, 2004
-----	-----	-----	-----	-----
Segment Total				
-----	-----	-----	-----	-----
<S> <C>	<C>	<C>	<C>	<C>
Medical \$ 448,202	\$ 112,488	\$ 107,418	\$ 110,220	\$ 118,076
Diagnostics 316,514	75,626	75,354	80,157	85,377
-----	-----	-----	-----	-----
Total \$ 764,716	\$ 188,114	\$ 182,772	\$ 190,377	\$ 203,453
=====	=====	=====	=====	=====

(\*) Restated to reflect a refinement of products classified as Safety.

Other Information

Included in the Ten-Year Summary of Selected Financial Data on page 22 of the Company's 2004 Annual Report, is the caption "Income from Continuing Operations Before Income Taxes". For the Company's fiscal year 2001, the amount referenced of \$535.2 million included footnote reference (C) which reads "Excludes the cumulative effect of accounting changes". The correct footnote reference should be (A) which reads "Includes cumulative effect of accounting change of \$36.8 (\$.14 per basic and diluted share)."

